TITLE

Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%

AUTHOR(S)
Jones, N. P.; Postlethwaite, R. J.; Noble, J. L.
PUB. DATE
May 1991
SOURCE
British Journal of Ophthalmology;May1991, Vol. 75 Issue 5, p311
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66065036

 

Related Articles

  • Evolution of Ocular Manifestations in Nephropathic Cystinosis: A Long-Term Study of a Population Treated With Cysteamine. Dureau, Pascal; Broyer, Michel; Dufier, Jean-Louis // Journal of Pediatric Ophthalmology & Strabismus;May/Jun2003, Vol. 40 Issue 3, p142 

    Background: Nephropathic cystinosis is characterized by an accumulation of cystine crystals within most body tissues. Renal transplantation and oral cysteamine have improved the general prognosis of the disease, and ocular manifestations are now the most common complication. This long-term...

  • Citations and Clinicians' Notes: Treatment | Novel Therapies.  // Current Medical Literature: Lysosomal Storage Disease;2003, Vol. 3 Issue 2, p58 

    Presents clinicians' notes on novel therapies for lysosomal storage diseases. Hematopoietic cell transplantation for inherited metabolic diseases; Clinical trial of a formulation of a topical cysteamine for the treatment of corneal cystine crystals in cystinosis; Uptake of recombinant...

  • Second International Cystinosis Research Symposium.  // Pediatric Nephrology;Oct2010, Vol. 25 Issue 10, p2195 

    The article presents abstracts on cystinosis research including a clinical study to compare cysteamine bitartrate delayed-release capsules to cysteamine bitartrate capsules, research on cysteamine toxicity in patients with cystinosis, and the assessment of psychosocial functioning in adolescents...

  • Cysteamine eye drops in the treatment of cystinosis - an Australian perspective. Radojkovic, Branko // Journal of Pharmacy Practice & Research;Dec2015, Vol. 45 Issue 4, p440 

    Cystinosis is a rare but very serious genetic disorder. Advancements in medical science, in the past few decades, have transformed this previously terminal condition into a manageable disease. Ophthalmic sequelae of cystinosis are caused by accumulation of cystine crystals in ocular tissues and...

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;11/15/2012, Vol. 69 Issue 22, p1934 

    The article mentions about the drugs, Cysteamine ophthalmic solution that helps in treatment of corneal cystine crystal accumulation in cystinosis patients and Loteprednol etabonate gel that helps in the treatment of postoperative inflammation and pain.

  • Sistinozisli Bir Olguda Pigmenter Makülopati. Demir, Selim; Beden, Ümit; Önmez, Baris; Yeter, Volkan; Erkan, Dilek // Retina-Vitreus/Journal of Retina-Vitreous;Jun2009, Vol. 17 Issue 2, p145 

    C ystinosis is a rare autosomal recessive lysosomal storage disorder. It is characterized by the intracellular accumulation of cystine. The gene for nephropathic cystinosis has been mapped to chromosome 17p13. Corneal and conjunctival crystals are the most common anterior segment findings while...

  • Orphan drug approved to treat rare kidney disorder.  // FDA Consumer;Nov94, Vol. 28 Issue 9, p3 

    States that Cystagon (cysteamine bitartrate) was approved by the Food and Drug Administration (FDA) on August 15, 1994 to treat children with nephropathic cystinosis. The Orphan Drug Act.

  • First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future. Kleta, Robert; Kaskel, Frederick; Dohil, Ranjan; Goodyer, Paul; Guay-Woodford, Lisa M.; Harms, Erik; Ingelfinger, Julie R.; Koch, Vera H.; Langman, Craig B.; Leonard, Mary B.; Mannon, Roslyn B.; Sarwal, Minnie; Schneider, Jerry A.; Skovby, Flemming; Sonies, Barbara C.; Thoene, Jess G.; Trauner, Doris A.; Gahl, William A. // Pediatric Nephrology;Apr2005, Vol. 20 Issue 4, p452 

    The article presents the consensus reached at first NIH/Office of Rare Diseases Conference on cystinosis, which was held on May 12-13, 2004. The meeting addressed the past, present, and future of nephropathic cystinosis research. In this meeting there was agreement on the importance of several...

  • Enzyme/Protein Replacement Therapy.  // Current Medical Literature: Lysosomal Storage Disease;2012, Vol. 10 Issue 3, p88 

    The article presents abstracts related to protein and enzyme replacement therapy which include cysteamine therapy to delay the progress of nephropathic cystinosis in adults and teenagers, the pharmacodynamics and pharmacokinetics of patients with nephropathic cystinosis, and the efficacy of...

  • Treatment of corneal cystine crystal accumulation in patients with cystinosis. Shams, Fatemeh; Livingstone, Iain; Oladiwura, Dilys; Ramaesh, Kanna // Clinical Ophthalmology;2014, Vol. 8, p2077 

    Cystinosis is a rare autosomal recessive disorder characterized by the accumulation of cystine within the cells of different organs. Infantile nephropathic cystinosis is the most common and severe phenotype. With the success of renal transplantation, these patients are now living longer and thus...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics